Anúncio
Anúncio
PCSA
Processa Pharmaceuticals, Inc. Common
3.36
USDPatrocinado
-0.10
-2.83%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
3.31
-0.05
-1.55%
Relatórios de Lucros PCSA
Rácio de surpresa positiva
PCSA separação 7 de 20 últimas estimativas.
35%
Próximo Relatório
Data do Próximo Relatório
18 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$1.40
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/-20.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/-92.43%
Processa Pharmaceuticals, Inc. Common earnings per share and revenue
On 06 de nov. de 2025, PCSA reported earnings of -1.75 USD per share (EPS) for Q3 25, beating the estimate of -2.04 USD, resulting in a 14.22% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -3.20% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -1.40 USD, with revenue projected to reach -- USD, implying an diminuir of -20.00% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Processa Pharmaceuticals, Inc. Common's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Processa Pharmaceuticals, Inc. Common reported EPS of -$1.75, beating estimates by 14.22%, and revenue of --, -- -- expectations.
How did the market react to Processa Pharmaceuticals, Inc. Common's Q3 2025 earnings?
The stock price moved down -3.2%, changed from $7.90 before the earnings release to $7.64 the day after.
When is Processa Pharmaceuticals, Inc. Common expected to report next?
The next earning report is scheduled for 18 de mar. de 2026.
What are the forecasts for Processa Pharmaceuticals, Inc. Common's next earnings report?
Based on 4
analistas, Processa Pharmaceuticals, Inc. Common is expected to report EPS of -$1.40 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio